What question did this study set out to answer?

This study aims to assess the prognostic value of the systemic immune-inflammation index (SII) in gastrointestinal cancers treated with immune checkpoint inhibitors.

June 27, 2026BMC GastroenterologyOpen Access

Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

JLJiamin LuChinese Academy of Sciences YFYuqian FengZhejiang Chinese Medical University KGKaibo GuoYanbian University

Discussion

Member takes

Implication

Systematic review identifies systemic immune-inflammation index as a key prognostic marker in gastrointestinal cancer treatment outcomes, suggesting improved patient management strategies.

Key Points

This study aims to assess the prognostic value of the systemic immune-inflammation index (SII) in gastrointestinal cancers treated with immune checkpoint inhibitors.
Performed a systematic review and meta-analysis of studies from Cochrane Library, Embase, and PubMed until August 15, 2025.
Included 28 studies with 4752 patients, focusing on baseline or treatment SII data and providing hazard ratios for survival outcomes.
Followed PRISMA guidelines for conducting the review and included only studies on GI cancer patients treated with ICIs.
High baseline SII levels were associated with worse overall survival (OS) and progression-free survival (PFS) in gastric cancer (OS: HR = 2.24, P=0.001; PFS: HR = 1.57, P=0.001).
In hepatocellular carcinoma, elevated SII predicted worse survival (OS: HR = 1.80, P=0.001; PFS: HR = 1.60, P=0.001).
Esophageal cancer also showed a significant relationship with high baseline SII levels (OS: HR = 1.79, P=0.001; PFS: HR = 1.50, P=0.003).

Cite This Study

Lu et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6772aea7db3c1953ef27 https://doi.org/10.1186/s12876-026-05014-x

View Full Paper

Ask AI

Bookmark

Implication

Systematic review identifies systemic immune-inflammation index as a key prognostic marker in gastrointestinal cancer treatment outcomes, suggesting improved patient management strategies.

Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Prognostic value of the systemic immune-inflammation index in gastrointestinal cancers treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider